Literature DB >> 11158211

Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study.

Luis M Ruilope1, Antonio Salvetti2, Kenneth Jamerson3, Lennart Hansson4, Ingrid Warnold5, Hans Wedel6, Alberto Zanchetti7.   

Abstract

This article reports further analyses of the Hypertension Optimal Treatment (HOT) Study data with the aim to describe (1) the value of baseline serum creatinine and its clearance (estimated by Cockroft and Gault formula) as predictors of cardiovascular events, (2) the effects of intensive lowering of BP on cardiovascular events and renal function in patients with reduced renal function, and (3) the effects on cardiovascular events of adding acetylsalicylic acid to antihypertensive therapy in patients with reduced renal function. The results show that (1) baseline elevation in serum creatinine and a reduction in estimated creatinine clearance are powerful predictors of cardiovascular events and death. (2) Reduced renal function at baseline did not preclude the desired control of BP. In contrast to patients with normal renal function, the incidence of major cardiovascular events did not differ in the three groups of patients with mild renal insufficiency randomized to different diastolic BP targets. No significant changes in serum creatinine were seen at the end of the 3.8-yr treatment period in the great majority of patients. However, there was a small group of patients (0.58% of the total study population) whose renal function deteriorated (increase > or =30% over baseline and final serum creatinine concentration > or =2 mg/dl) despite satisfactory reduction of diastolic BP. (3) The results of this reanalysis of the HOT Study suggest though do not prove that the association of acetylsalicylic acid with intensive antihypertensive therapy offers additional benefit in hypertensive patients with reduced renal function.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11158211     DOI: 10.1681/ASN.V122218

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  80 in total

Review 1.  Hyperuricemia and renal function.

Authors:  L M Ruilope; J Garcia-Puig
Journal:  Curr Hypertens Rep       Date:  2001-06       Impact factor: 5.369

2.  Minor renal dysfunction: an emerging independent cardiovascular risk factor.

Authors:  E Ritz
Journal:  Heart       Date:  2003-09       Impact factor: 5.994

3.  Heart disease and stroke statistics--2012 update: a report from the American Heart Association.

Authors:  Véronique L Roger; Alan S Go; Donald M Lloyd-Jones; Emelia J Benjamin; Jarett D Berry; William B Borden; Dawn M Bravata; Shifan Dai; Earl S Ford; Caroline S Fox; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Diane M Makuc; Gregory M Marcus; Ariane Marelli; David B Matchar; Claudia S Moy; Dariush Mozaffarian; Michael E Mussolino; Graham Nichol; Nina P Paynter; Elsayed Z Soliman; Paul D Sorlie; Nona Sotoodehnia; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner
Journal:  Circulation       Date:  2011-12-15       Impact factor: 29.690

4.  Heart disease and stroke statistics--2011 update: a report from the American Heart Association.

Authors:  Véronique L Roger; Alan S Go; Donald M Lloyd-Jones; Robert J Adams; Jarett D Berry; Todd M Brown; Mercedes R Carnethon; Shifan Dai; Giovanni de Simone; Earl S Ford; Caroline S Fox; Heather J Fullerton; Cathleen Gillespie; Kurt J Greenlund; Susan M Hailpern; John A Heit; P Michael Ho; Virginia J Howard; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Diane M Makuc; Gregory M Marcus; Ariane Marelli; David B Matchar; Mary M McDermott; James B Meigs; Claudia S Moy; Dariush Mozaffarian; Michael E Mussolino; Graham Nichol; Nina P Paynter; Wayne D Rosamond; Paul D Sorlie; Randall S Stafford; Tanya N Turan; Melanie B Turner; Nathan D Wong; Judith Wylie-Rosett
Journal:  Circulation       Date:  2010-12-15       Impact factor: 29.690

5.  Chronic kidney disease epidemic: myth and reality.

Authors:  Filippo Mangione; Antonio Dal Canton
Journal:  Intern Emerg Med       Date:  2011-10       Impact factor: 3.397

Review 6.  Cardiorenal syndrome: still not a defined entity.

Authors:  Carlo Longhini; Christian Molino; Fabio Fabbian
Journal:  Clin Exp Nephrol       Date:  2010-02-20       Impact factor: 2.801

7.  Cystatin C-based CKD-EPI equations and N-terminal pro-B-type natriuretic peptide for predicting outcomes in acutely decompensated heart failure.

Authors:  Pedro J Flores-Blanco; Sergio Manzano-Fernández; Juan I Pérez-Calvo; Francisco J Pastor-Pérez; Francisco J Ruiz-Ruiz; Francisco J Carrasco-Sánchez; José L Morales-Rull; Domingo Pascual-Figal; Luis Galisteo-Almeda; James L Januzzi
Journal:  Clin Cardiol       Date:  2015-02-06       Impact factor: 2.882

Review 8.  Sudden cardiac death in chronic kidney disease: epidemiology and prevention.

Authors:  M Khaled Shamseddin; Patrick S Parfrey
Journal:  Nat Rev Nephrol       Date:  2011-02-01       Impact factor: 28.314

Review 9.  Obesity paradox in end-stage kidney disease patients.

Authors:  Jongha Park; Seyed-Foad Ahmadi; Elani Streja; Miklos Z Molnar; Katherine M Flegal; Daniel Gillen; Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Prog Cardiovasc Dis       Date:  2013-10-09       Impact factor: 8.194

10.  Plasma metabolomic profiles in different stages of CKD.

Authors:  Vallabh O Shah; Raymond R Townsend; Harold I Feldman; Kirk L Pappan; Elizabeth Kensicki; David L Vander Jagt
Journal:  Clin J Am Soc Nephrol       Date:  2012-12-06       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.